Oura Ring Gen 4 sensor data, not clinical measurementsN=1 case study, not validated for clinical decisionsHEV diagnosed Mar 18; Day 109 post-ruxolitinibMore
Consumer wearable data can support exploratory review only. The HEV diagnosis, temporally confounded with treatment start, remains a material confounder.

Sleep Architecture as Health Signal

Module 3: Comparative Sleep Analysis
P1 AVG SLEEP
Below target
6.0hrs
Target: 7-9 hrs
P1 EFFICIENCY
Watch
78.9%
12% nights below 75%
P1 DEEP SLEEP
In range
15.1%
Norm: 13-23%
P2 AVG SLEEP
Below target
6.7hrs
Target: 7-9 hrs
P2 EFFICIENCY
Watch
82.8%
10% nights below 75%
P2 DEEP SLEEP
In range
18.8%
Norm: 13-23%
P3 AVG SLEEP
Below target
6.2hrs
Target: 7-9 hrs
P3 EFFICIENCY
Watch
84.0%
0% nights below 75%
P3 DEEP SLEEP
Watch
12.0%
Norm: 13-23%
ARCHITECTURE

Sleep Architecture Over Time


EFFICIENCY

Sleep Efficiency Trends

TIMING

Sleep Timing Analysis

BENCHMARKS

Benchmark Comparison

Metric General Norms Patient 1 (post-HSCT)Patient 2 (post-Stroke)Patient 3 (Healthy Control)
Deep Sleep %13 - 2315.1 (z=-0.6)18.8 (z=+0.2)12.0 (z=-1.2)
REM Sleep %20 - 2511.9 (z=-4.3)17.2 (z=-2.1)12.9 (z=-3.8)
Efficiency %85 - 10078.9 (z=-1.8)82.8 (z=-1.3)84.0 (z=-1.1)
Total Hours7 - 96.0 (z=-2.0)6.7 (z=-1.3)6.2 (z=+0.0)
RECOVERY

Recovery Trajectory

STATS

Statistical Comparison

Metric Patient 1 Patient 2 p-value Cohen's d Cliff's Δ 95% CI (median diff)
Deep Sleep % 15.1 18.8 p<0.001 *** -0.65 (medium) -0.37 (medium) [-4.9, -2.1]
REM Sleep % 11.9 17.2 p<0.001 *** -1.29 (large) -0.67 (large) [-7.2, -4.5]
Light Sleep % 52.0 46.8 p<0.001 *** +0.80 (large) +0.43 (medium) [+2.4, +6.7]
Awake % 21.1 17.2 p<0.001 *** +0.62 (medium) +0.50 (large) [+4.0, +5.9]
Efficiency 78.9 82.8 p<0.001 *** -0.62 (medium) -0.50 (large) [-6.0, -4.0]
Total Hours 6.0 6.7 p<0.001 *** -0.64 (medium) -0.38 (medium) [-1.1, -0.5]
Bedtime Hour 24.7 23.9 p<0.001 *** +0.57 (medium) +0.37 (medium) [+0.7, +1.4]

* p<0.05, ** p<0.01, *** p<0.001 · CI = bootstrap 95% confidence interval for median difference (Patient 1 - Patient 2)

INTERPRETATION

Clinical Interpretation

  • Patient 1 (post-HSCT): REM sleep (11.9%) is below population norms (20.0-25.0%), suggesting possible autonomic interference with dream-stage cycling.
  • Patient 1 (post-HSCT): Sleep efficiency (79%) is below the recommended 85% threshold.
  • Patient 1 (post-HSCT): Average daily sleep debt of 59 minutes below the 7-hour target, accumulating chronic sleep restriction.
  • Patient 1 (post-HSCT): High bedtime variability (SD=116 min) suggests inconsistent sleep schedule, which may impair circadian entrainment.
  • Patient 2 (post-Stroke): REM sleep (17.2%) is below population norms (20.0-25.0%), suggesting possible autonomic interference with dream-stage cycling.
  • Patient 2 (post-Stroke): Sleep efficiency (83%) is below the recommended 85% threshold.
  • Patient 2 (post-Stroke): Efficiency trend is statistically declining (-0.06%/week, p=0.000).
  • Patient 2 (post-Stroke): High bedtime variability (SD=77 min) suggests inconsistent sleep schedule, which may impair circadian entrainment.
  • Patient 3 (Healthy Control): Deep sleep (12.0%) is below the general population norm (13.0-23.0%), consistent with post-treatment sleep disruption.
  • Patient 3 (Healthy Control): REM sleep (12.9%) is below population norms (20.0-25.0%), suggesting possible autonomic interference with dream-stage cycling.
  • Patient 3 (Healthy Control): Sleep efficiency (84%) is below the recommended 85% threshold.
  • Patient 3 (Healthy Control): Average daily sleep debt of 49 minutes below the 7-hour target, accumulating chronic sleep restriction.
  • Patient 3 (Healthy Control): High bedtime variability (SD=65 min) suggests inconsistent sleep schedule, which may impair circadian entrainment.
  • Deep sleep percentage differs significantly between patients (p=0.000, Cohen's d=-0.65, medium effect).
  • Sleep efficiency differs significantly (p=0.000, Cohen's d=-0.62, medium effect).
METHODOLOGY

Methodology & Limitations

Data Source

Sleep architecture data from Oura Ring wearable sensors (oura_sleep_periods table, type='long_sleep'). Durations are recorded in seconds by the Oura API and converted to hours/percentages for analysis.

Architecture Percentages

Computed as stage_duration / (total_sleep_duration + awake_time) × 100, ensuring all stages sum to 100% of time in bed.

Statistical Tests

  • Mann-Whitney U: Non-parametric test for distribution differences (does not assume normality)
  • Cohen's d: Standardized mean difference (pooled SD); |d| < 0.2 = negligible, < 0.5 = small, < 0.8 = medium, else large
  • Cliff's delta: Non-parametric effect size based on rank ordering
  • Bootstrap CI: 5,000-iteration bootstrap for median difference confidence interval
  • Linear regression: Ordinary least squares for efficiency trend
  • Spearman rank correlation: Monotonic trend detection for recovery trajectory

Bedtime Handling

Bedtime hours past midnight are encoded as 24+ (e.g., 00:30 = 24.5) to avoid discontinuities in variability and midpoint calculations.

Population Norms

  • General (age 30-39): Deep 13-23%, REM 20-25%, Efficiency ≥85%, Total 7-9h (Ohayon et al. 2004, Hirshkowitz et al. 2015)
  • Post-HSCT: Deep 8-15%, REM 10-18%, Efficiency 70-82% (Jim et al. 2014, Rischer et al. 2020)
  • Post-stroke: Deep 10-18%, REM 12-20%, Efficiency 72-85% (Leppavuori et al. 2002, Duss et al. 2018)

Limitations

  • N=2 case study: findings are descriptive, not generalizable
  • Oura Ring is a consumer wearable, not a polysomnograph; sleep staging has known accuracy limitations
  • Different observation windows and data density between patients
  • No control for confounders (medications, environment, activity levels)
  • Population norms are age-adjusted approximations, not individual-level standards